1. Home
  2. MIRA
  3. MIRA News

Latest MIRA Pharmaceuticals Inc. (MIRA) News on May 15, 2025

MIRA

Market Exclusive

4 days ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector

Psychedelic: Compass, GH Research, MindMed report quarterly earnings
MIRA

TipRanks

6 days ago

Psychedelic: Compass, GH Research, MindMed report quarterly earnings

MIRA

ACCESS Newswire

7 days ago

MIRA Pharmaceuticals Announces Board Approval of SKNY Acquisition Reflecting $60+ Million in Combined Enterprise Value Based on Independent Review

EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million
MIRA

Benzinga

7 days ago

EXCLUSIVE: Mira Pharmaceuticals Board Approves SKNY Pharma Acquisition, Establishing Combined Enterprise Value Over $60 Million

MIRA

ACCESS Newswire

9 days ago

MIRA Pharmaceuticals Reports No Brain Toxicity in FDA-Required Study of Ketamir-2, Confirming Absence of Ketamine-Linked Neurotoxicity

EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study
MIRA

Benzinga

9 days ago

EXCLUSIVE: MIRA Pharmaceuticals Lead Program Ketamir-2 Shows No Brain Toxicity In FDA-Mandated Study

MIRA

Zacks Small Cap Research

9 days ago

MIRA Sets Up Success With Stellar Safety Results

Psychedelic: Clearmind completes clinical site initiations for AUD trial
MIRA

TipRanks

20 days ago

Psychedelic: Clearmind completes clinical site initiations for AUD trial

MIRA

ACCESS Newswire

22 days ago

MIRA Pharmaceuticals Reports Positive In Vitro Drug Release Data for Topical Ketamir-2, Targeting $11B+ U.S. Topical Pain Relief Market and Exploring FDA Fast Track Designation

MIRA

Zacks Small Cap Research

22 days ago

MIRA Pain Treatment Expands Market Size Potential

MIRA

MT Newswires

a month ago

Mira Says Diabetes Treatment Ketamir-2 Shows Significant Reduction in Neuropathic Pain Symptoms in Animal Model

MIRA

ACCESS Newswire

a month ago

MIRA Pharmaceuticals Announces Positive Results for Ketamir-2 in Diabetic Neuropathy Animal Model, Reinforcing Confidence Ahead of Phase I Completion

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study
MIRA

Benzinga

a month ago

EXCLUSIVE: MIRA Pharmaceuticals Ketamir-2 Shows Efficacy In Diabetes-Associated Nerve Damage In Animal Study

MIRA

Zacks Small Cap Research

a month ago

MIRA Continues Positive Testing Run

Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2
MIRA

TipRanks

a month ago

Mira Pharmaceuticals enrolls first subjects in Phase 1 trial of Ketamir-2

MIRA

ACCESS Newswire

a month ago

MIRA Pharmaceuticals Enrolls First Subjects in Phase 1 Clinical Trial of Ketamir-2 for Neuropathic Pain

MIRA

Zacks Small Cap Research

a month ago

MIRA Enrolls Patients Amid Rapid Progress

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit
MIRA

TipRanks

2 months ago

Morning Movers: 23andMe plummets after Chapter 11 proceedings and CEO exit

MIRA

MT Newswires

2 months ago

Mira Pharmaceuticals Signs LOI to Acquire Skny Pharmaceuticals

MIRA

ACCESS Newswire

2 months ago

MIRA Pharmaceuticals Signs Binding Letter of Intent to Acquire SKNY Pharmaceuticals, Securing a $5 Million Capital Infusion to Advance Weight Loss and Smoking Cessation Drug Development

EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug
MIRA

Benzinga

2 months ago

EXCLUSIVE: MIRA Pharmaceuticals Signs To Acquire SKNY Pharmaceuticals, Expand Pipeline Into Weight Loss And Smoking Cessation Drug

MIRA

Zacks Small Cap Research

2 months ago

MIRA Makes Significant Acquisition and Boosts Capital

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial
MIRA

TipRanks

2 months ago

Psychedelic: atai reports dosing of first patient in Phase 2 VLS-01 trial

MIRA

MT Newswires

2 months ago

Mira Pharmaceuticals Develops Topical Formulation of Ketamir-2 for Pain Relief

MIRA

Zacks Small Cap Research

2 months ago

MIRA Makes Another Pain Management Stride

MIRA

ACCESS Newswire

2 months ago

MIRA Pharmaceuticals Expands Ketamir-2 Development with Topical Treatment for Localized Neuropathic and Inflammatory Pain

MIRA

ACCESS Newswire

2 months ago

MIRA Pharmaceuticals Announces Approval and Initiation of Phase 1 Clinical Trial for Ketamir-2 in Neuropathic Pain

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain
MIRA

Benzinga

2 months ago

EXCLUSIVE: MIRA Pharmaceuticals Kick Starts Human Trial In Israel For Ketamir-2 For Neuropathic Pain

MIRA

Zacks Small Cap Research

2 months ago

MIRA Announces Approval of Important Testing

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation
MIRA

Simply Wall St.

4 months ago

Here's Why We're Not Too Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Situation

Memecoin Degens Raise Millions for Rare Cancer Research After a Father’s Plea
MIRA

CoinDesk

5 months ago

Memecoin Degens Raise Millions for Rare Cancer Research After a Father’s Plea

MIRA

ACCESSWIRE

5 months ago

MIRA Pharmaceuticals Submits IND for Ketamir-2 to FDA, Marking a Significant Milestone in the Company's Pipeline Development

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment
MIRA

Benzinga

5 months ago

EXCLUSIVE: MIRA Pharmaceuticals Files FDA Application To Start Human Trials For Its Lead Pain Treatment

MIRA

Zacks Small Cap Research

5 months ago

MIRA Makes Major Strides

MIRA

ACCESSWIRE

5 months ago

MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile With No Adverse Findings, Paving the Way for IND Submission by Year-End

EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain
MIRA

Benzinga

5 months ago

EXCLUSIVE: MIRA Pharmaceuticals Validates Ketamir-2's Safety Profile, Paving Way For Human Trials In Neuropathic Pain

MIRA

ACCESSWIRE

6 months ago

MIRA Reveals Innovative Phase I/IIa Protocol Design and Selection of Clinical Trial Site

MIRA

Zacks Small Cap Research

6 months ago

MIRA Continues Solid Financial Management

MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials
MIRA

GuruFocus.com

7 months ago

MIRA Pharmaceuticals Shares Surge 40% After Ketamir-2 Excels in Pain Management Trials

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain
MIRA

Benzinga

7 months ago

MIRA Pharmaceuticals' Formulated Shows Greater Efficacy Than FDA-Approved Drug For Chemo-Induced Neuropathic Pain

MIRA

ACCESSWIRE

7 months ago

MIRA Pharmaceuticals' Ketamir-2 Shows 60% Greater Efficacy Than FDA-Approved Gabapentin in Reversing Chemotherapy-Induced Neuropathic Pain

MIRA

Market Exclusive

7 months ago

Weekly Roundup on the Cannabis Sector & Psychedelic Sector 10-28-2024

MIRA

ACCESSWIRE

7 months ago

MIRA Pharmaceuticals Announces Ketamir-2 Outperforms Current FDA-Approved Neuropathic Pain Treatments, Gabapentin and Pregabalin, in Preclinical Study

MIRA

Zacks Small Cap Research

7 months ago

MIRA Continues to Post Outstanding Test Results

MIRA

MT Newswires

8 months ago

MIRA Pharma Says Ketamir-2 Achieved 100% Neuropathic Pain Reversal in Preclinical Models

MIRA

ACCESSWIRE

8 months ago

MIRA Pharmaceuticals Announces New Preclinical Data for Ketamir-2 to Be Presented at the 18th Annual Pain Therapeutics Summit in Boston on October 28-29, 2024

MIRA

Zacks Small Cap Research

8 months ago

MIRA Makes Impressive Progress

MIRA

ACCESSWIRE

8 months ago

MIRA Pharmaceuticals Advances Ketamir-2 Development Following Phase 1 Design Completion, Focusing on Early Clinical Efficacy Demonstration for Neuropathic Pain in 2025

MIRA

MT Newswires

8 months ago

MIRA Pharmaceuticals Selects Neuropathic Pain as Initial Indication of Ketamir-2

MIRA

ACCESSWIRE

8 months ago

MIRA Pharmaceuticals Designates Neuropathic Pain as Primary Indication for Ketamir-2 and Submits Pre-IND Meeting Request to FDA

MIRA

MT Newswires

9 months ago

MIRA Pharmaceuticals Shares Surge Pre-Bell on 'Significant' Ketamir-2 Study Data

MIRA

ACCESSWIRE

9 months ago

MIRA Pharmaceuticals Achieves 100% Reversal of Neuropathic Pain With Oral Ketamir-2 in Breakthrough Study

MIRA

Zacks Small Cap Research

9 months ago

MIRA Announces Significant Test Results

MIRA

ACCESSWIRE

9 months ago

MIRA Pharmaceuticals Showcases Significant Progress and Announces Final Phase of Regulatory Work as It Prepares for IND Submission by Year-End

MIRA

Zacks Small Cap Research

9 months ago

MIRA Continues to Reveal Advances in Treatment

MIRA

ACCESSWIRE

9 months ago

MIRA Pharmaceuticals Unveils Ketamir-2's Principal Metabolite: Nor-Ketamir - a Longer-Acting, Brain Penetrating and Selective Compound Acting on the NMDA PCP Receptor

PayPal, Kellanova upgraded: Wall Street's top analyst calls
MIRA

The Fly

9 months ago

PayPal, Kellanova upgraded: Wall Street's top analyst calls

Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data
MIRA

Benzinga

10 months ago

Mental Health Disorders-Focused MIRA Pharmaceuticals Unveils Additional Preclinical Data

MIRA

ACCESSWIRE

10 months ago

MIRA Pharmaceuticals Announces Positive Discovery of Ketamir-2’s Selective NMDA Binding Mechanism of Action

We're Not Very Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Rate
MIRA

Simply Wall St.

10 months ago

We're Not Very Worried About MIRA Pharmaceuticals' (NASDAQ:MIRA) Cash Burn Rate

MIRA

MT Newswires

10 months ago

Sector Update: Health Care Stocks Rise Late Afternoon

MIRA

MT Newswires

10 months ago

MIRA Pharmaceuticals Shares Quadruple on More 'Promising' Ketamir-2 Study Results

Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders
MIRA

Benzinga

10 months ago

Nano-Cap MIRA Pharmaceuticals' Oral Ketamine Analog Shows Potential In Neuropsychiatric Disorders

MIRA

ACCESSWIRE

10 months ago

MIRA Pharmaceuticals Reveals Preclinical Success: Ketamir-2 Optimized for Brain Delivery, Avoiding Ketamine's Drug Resistance

MIRA

Zacks Small Cap Research

10 months ago

MIRA Posts More Positive Test Results

MIRA

Zacks Small Cap Research

10 months ago

MIRA Announces More Positive Test Results

MIRA

ACCESSWIRE

10 months ago

Mira Pharmaceuticals Announces Promising Results for MIRA-55 in Multiple Preclinical Tests Compared to THC

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing
MIRA

PR Newswire

a year ago

MIRA Pharmaceuticals Announces Ketamir-2 Shows Promising Safety Profile in Comparison to Traditional Ketamine In Preclinical Testing

MIRA

Zacks Small Cap Research

a year ago

MIRA Announces Positive Test Results

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year
MIRA

PR Newswire

a year ago

Mira Pharmaceuticals Announces Positive Preclinical Study Results For Its Novel Oral ketamine Analog, Ketamir-2, Paving the Way for IND Submission Later This Year

MIRA

MT Newswires

a year ago

Sector Update: Health Care Stocks Retreat Wednesday Afternoon

MIRA

MT Newswires

a year ago

Mira Pharmaceuticals Says US DEA Finds Marijuana Analog a Non-Controlled Substance

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance
MIRA

PR Newswire

a year ago

Mira Pharmaceuticals Announces DEA Rules MIRA-55, a Novel Oral Pharmaceutical Marijuana Analog, Is Not Classified as a Controlled Substance

MIRA

Zacks Small Cap Research

a year ago

MIRA Announces Important Collaboration Potential

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog
MIRA

PR Newswire

a year ago

MIRA Pharmaceuticals in Discussions with Memorial Sloan Kettering to Collaborate on Preclinical Cancer Pain Model Utilizing The Company's Novel Oral Ketamine Analog

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog
MIRA

PR Newswire

a year ago

Mira Pharmaceuticals Advances Preclinical Trials Towards an IND Submission This Year for Ketamir-2, a Differentiated Oral Ketamine Analog

MIRA

Zacks Small Cap Research

a year ago

MIRA Focuses on Potential Game-Changing Drug Submission

MIRA

Zacks Small Cap Research

a year ago

MIRA Making Strides Toward Breakthrough Treatment

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission
MIRA

PR Newswire

a year ago

Mira Pharmaceuticals Announces Encouraging Preclinical Results Advancing Ketamir-2 Towards Potential Year-End IND Submission

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor
MIRA

PR Newswire

a year ago

MIRA Pharmaceuticals Welcomes Dr. Itzchak Angel, former Head of Pharmacology at Synthelabo, as Chief Scientific Advisor

Is MIRA Pharmaceuticals (NASDAQ:MIRA) In A Good Position To Deliver On Growth Plans?
MIRA

Simply Wall St.

a year ago

Is MIRA Pharmaceuticals (NASDAQ:MIRA) In A Good Position To Deliver On Growth Plans?

MIRA Pharmaceuticals Provides Corporate Update
MIRA

PR Newswire

a year ago

MIRA Pharmaceuticals Provides Corporate Update

Charles River (CRL) to Report Q4 Earnings: What's in Store?
MIRA

Zacks

a year ago

Charles River (CRL) to Report Q4 Earnings: What's in Store?

11 Best Wine Stocks to Buy Now
MIRA

Insider Monkey

a year ago

11 Best Wine Stocks to Buy Now

/C O R R E C T I O N -- Nutex Health, Inc./
MIRA

PR Newswire

a year ago

/C O R R E C T I O N -- Nutex Health, Inc./

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?
MIRA

Zacks

a year ago

Strength Seen in Repligen (RGEN): Can Its 4.3% Jump Turn into More Strength?

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update
MIRA

Zacks

a year ago

Unicycive (UNCY) Up on Positive Hyperphosphatemia Study Update

MIRA

Newsfile

a year ago

La Rosa to Present at the Microcap Conference in Atlantic City

LiqTech to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024
MIRA

PR Newswire

a year ago

LiqTech to Participate in a Fireside Chat at the Lytham Partners 2024 Investor Select Conference on February 1, 2024

MIRA

Business Wire

a year ago

Apyx Medical Corporation Announces Peer-Reviewed Clinical Publication Evaluating the Safety of Renuvion® Following Liposuction in Multiple Areas of the Body

Kirkland's Home Promotes Amy Sullivan to CEO
MIRA

PR Newswire

a year ago

Kirkland's Home Promotes Amy Sullivan to CEO

Kirkland's Home Announces Holiday 2023 Comparable Sales Results
MIRA

PR Newswire

a year ago

Kirkland's Home Announces Holiday 2023 Comparable Sales Results

La Rosa Opens Office in the Tampa Bay Area
MIRA

GlobeNewswire

a year ago

La Rosa Opens Office in the Tampa Bay Area

Genius Group Announces Closing of $8.25 Million Public Offering
MIRA

GlobeNewswire

a year ago

Genius Group Announces Closing of $8.25 Million Public Offering

Electra Appoints Heather Smiles as Vice President, Investor Relations & Corporate Development
MIRA

Business Wire

a year ago

Electra Appoints Heather Smiles as Vice President, Investor Relations & Corporate Development

Caravelle International Group Announces a Private Placement of up to $6.8 Million
MIRA

PR Newswire

a year ago

Caravelle International Group Announces a Private Placement of up to $6.8 Million

Investors Will Want Taitron Components' (NASDAQ:TAIT) Growth In ROCE To Persist
MIRA

Simply Wall St.

a year ago

Investors Will Want Taitron Components' (NASDAQ:TAIT) Growth In ROCE To Persist

MIRA

Business Wire

a year ago

Apyx Medical Corporation Reports Preliminary Fourth Quarter and Full Year 2023 Revenue Results

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
MIRA

GlobeNewswire

a year ago

Assertio Holdings, Inc. Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO
MIRA

Zacks

a year ago

Assertio (ASRT) Shares Fall as Dan Peisert Steps Down as CEO

Share on Social Networks: